Matrix Pharma Corp.

Matrix Pharma Corp. , based in India, specializes in producing Active Pharmaceutical Ingredients (APIs) essential for formulating a wide range of medications, enhancing global healthcare delivery and accessibility. Founded in 2022 in Hyderabad, India, Matrix Pharma Corp focuses on manufacturing Active Pharmaceutical Ingredients (APIs). The company has engaged in 1 deal, with its most recent funding round occurring on August 29, 2025, where it raised INR 14.

5 billion from Kotak Alternate Asset Managers. The firm has not undergone any noted changes in business strategy or operations since its inception. Matrix Pharma Corp produces a variety of Active Pharmaceutical Ingredients (APIs) crucial for a multitude of medications, including antiretrovirals, antivirals, antidiabetics, antineoplastics, antihypertensives, cardiovascular products, central nervous system treatments, and proton pump inhibitors. Their offerings cater to leading pharmaceutical companies spanning over 80 countries, strategically marketed in regions such as North America, Europe, and parts of Asia to enhance healthcare access.

Matrix Pharma Corp operates primarily through B2B transactions with pharmaceutical companies, supplying APIs under contractual agreements based on volume commitments and delivery schedules. Revenue is generated from negotiated pricing for bulk API orders, which are essential for maintaining consistent revenue streams in the competitive global market for high-quality pharmaceutical ingredients. In August 2025, Matrix Pharma Corp raised INR 14. 5 billion, which will be utilized to support the development of new API products and facilitate expansion into new markets.

Specific targets for market growth include increasing presence in emerging regions and enhancing relationships with pharmaceutical partners, with plans to implement these strategies by the end of 2026.